恶性黑色素瘤免疫治疗超进展研究现状

doi:10.11904/j.issn.1002-3070.2023.02.009

摘要/Abstract

摘要： 恶性黑色素瘤是一种恶性程度极高的实体肿瘤,侵袭性强,预后差。随着免疫治疗药物的上市,恶性黑色素瘤患者的总生存率得到了极大的提升。然而,部分患者在免疫治疗后短期内进展迅速,病情迅速恶化,称为超进展。超进展患者生存率降低,预后更差,为及时发现和预防超进展的发生,降低患者死亡率,本文对恶性黑色素瘤免疫治疗超进展研究现状进行综述。

关键词: 恶性黑色素瘤, 免疫治疗, 超进展

Abstract: Malignant melanoma is a highly malignant solid tumor with strong invasiveness and poor prognosis.With marketing of immunotherapy drugs,the overall survival rate of malignant melanoma patients has been greatly improved.However,some patients progress rapidly and deteriorate rapidly after immunotherapy,which is called hyperprogressive disease.The survival rate of hyperprogressive patients is lower and their prognosis is worse.In order to detect and prevent the occurrence of hyperprogressionin time and reduce the mortality of patients,this article reviews the research status immunotherapy for hyperprogression of malignant melanoma.

Key words: Malignant melanoma, Immunotherapy, Hyperprogression

中图分类号:

R739.5

李路桥, 邹征云. 恶性黑色素瘤免疫治疗超进展研究现状[J]. 实用肿瘤学杂志, 2023, 37(2): 144-148.

LI Luqiao, ZOU Zhengyun. Current status of advanced research on immunotherapy for malignant melanoma[J]. Journal of Practical Oncology, 2023, 37(2): 144-148.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.02.009

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I2/144

参考文献

1 Xue Y,Gao S,Gou J,et al.Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors:preclinical and clinical studies and mechanism of action[J].Expert Opin Drug Deliv,2021,18(2):187-203.
2 Champiat S,Dercle L,Ammari S,et al.Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1[J].Clin Cancer Res,2017,23(8):1920-1928.
3 Ferrara R,Mezquita L,Texier M,et al.Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy[J].JAMA Oncol,2018,4(11):1543-1552.
4 Gandara D,Reck M,Moro-Sibilot D,et al.Fast progression in non-small cell lung cancer:results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel[J].J Immunother Cancer,2021,9(3):e001882.
5 Mellema WW,Burgers SA,Smit EF.Tumor flare after start of RAF inhibition in KRAS mutated NSCLC:a case report[J].Lung Cancer,2015,87(2):201-203.
6 Novik AV,Protsenko SA,Baldueva IA,et al.Vemurafenib-induced progression of breast cancer:a case report and review of the literature[J].Target Oncol,2016,11(2):235-238.
7 Kanjanapan Y,Day D,Wang L,et al.Hyperprogressive disease in early-phase immunotherapy trials:clinical predictors and association with immune-related toxicities[J].Cancer,2019,125(8):1341-1349.
8 Saada-Bouzid E,Defaucheux C,Karabajakian A,et al.Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma[J].Ann Oncol,2017,28(7):1605-1611.
9 Kato S,Goodman A,Walavalkar V,et al.Hyperprogressors after immunotherapy:analysis of genomic alterations associated with accelerated growth rate[J].Clin Cancer Res,2017,23(15):4242-4250.
10 Matos I,Martin-Liberal J,Garcia-Ruiz A,et al.Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria[J].Clin Cancer Res,2020,26(8):1846-1855.
11 Kim CG,Kim C,Yoon SE,et al.Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma[J].J Hepatol,2021,74(2):350-359.
12 Kamada T,Togashi Y,Tay C,et al.PD-1(+)regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer[J].Proc Natl Acad Sci U S A,2019,116(20):9999-10008.
13 Larkin J,Chiarion-Sileni V,Gonzalez R,et al.Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J].N Engl J Med,2015,373(1):23-34.
14 Huang RY,Francois A,McGray AR,et al.Compensatory upregulation of PD-1,LAG-3,and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer[J].Oncoimmunology,2017,6(1):e1249561.
15 Li Q,Ngo PT,Egilmez NK.Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy[J].Cancer Immunol Immunother,2021,70(6):1789-1796.
16 Lamberti G,Sisi M,Andrini E,et al.The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC):which are the involved players?[J].Cancers (Basel),2020,12(11):3129.
17 Lo Russo G,Moro M,Sommariva M,et al.Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade[J].Clin Cancer Res,2019,25(3):989-999.
18 Bakema JE,van Egmond M.Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer[J].Curr Top Microbiol Immunol,2014,382:373-392.
19 Xiong D,Wang Y,Singavi AK,et al.Immunogenomic landscape contributes to hyperprogressive disease after anti-PD-1 immunotherapy for cancer[J].iScience,2018,9:258-277.
20 Wartewig T,Kurgyis Z,Keppler S,et al.PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis[J].Nature,2017,552(7683):121-125.
21 Landre T,Taleb C,Nicolas P,et al.Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour?[J].J Clin Oncol,2016,34(15_suppl):3070-3070.
22 Padron A,Hurez V,Gupta HB,et al.Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model[J].Exp Gerontol,2018,105:146-154.
23 Conforti F,Pala L,Bagnardi V,et al.Cancer immunotherapy efficacy and patients′sex:a systematic review and meta-analysis[J].Lancet Oncol,2018,19(6):737-746.
24 Yilmaz M,Akovali B.Hyperprogression after nivolumab for melanoma:a case report[J].J Oncol Pharm Pract,2020,26(1):244-251.
25 Larkin J,Chiarion-Sileni V,Gonzalez R,et al.Five-year survival with combined nivolumab and ipilimumab in advanced melanoma[J].N Engl J Med,2019,381(16):1535-1546.
26 Wagner NB,Forschner A,Leiter U,et al.S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies[J].Br J Cancer,2018,119(3):339-346.
27 Sasaki A,Nakamura Y,Mishima S,et al.Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer[J].Gastric Cancer,2019,22(4):793-802.
28 Kim JY,Lee KH,Kang J,et al.Hyperprogressive disease during anti-PD-1 (PDCD1)/ PD-L1 (CD274)therapy:a systematic review and meta-analysis[J].Cancers (Basel),2019,11(11):1699.
29 石琳娜,隋红.原发性肝癌免疫检查点抑制剂治疗的进展与挑战[J].实用肿瘤学杂志,2020,34(6):560-564.
30 Margetts J,Ogle LF,Chan SL,et al.Neutrophils:driving progression and poor prognosis in hepatocellular carcinoma?[J].Br J Cancer,2018,118(2):248-257.
31 尹蕾,杨旭东,杨悦,等.中性粒细胞与淋巴细胞比值在非小细胞肺癌患者预后评估中的临床意义及相关机制研究[J].实用肿瘤学杂志,2021,35(2):117-124.
32 Forschner A,Hilke FJ,Bonzheim I,et al.MDM2,MDM4 and EGFR amplifications and hyperprogression in metastatic acral and mucosal melanoma[J].Cancers (Basel),2020,12(3):540.
33 Fang DD,Tang Q,Kong Y,et al.MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment[J].J Immunother Cancer,2019,7(1):327.
34 Wang X,Wang F,Zhong M,et al.The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy[J].Mol Cancer,2020,19(1):81.
35 Singavi AK,Menon S,Kilari D,et al.Predictive biomarkers for hyper-progression (HP)in response to immune checkpoint inhibitors (ICI)– analysis of somatic alterations (SAs)[J].Ann Oncol,2017,28:405.
36 Cabel L,Proudhon C,Romano E,et al.Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy[J].Nat Rev Clin Oncol,2018,15(10):639-650.
37 Nakamoto R,L CZ,Rosenberg J,et al.Imaging characteristics and diagnostic performance of 2-deoxy-2-[¹⁸F]fluoro-D-glucose PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy[J].Mol Imaging Biol,2021,23(1):139-147.
38 Ogawara D,Soda H,Iwasaki K,et al.Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy[J].Thorac Cancer,2018,9(1):175-180.

[1]	王嘉倍, 张运广, 刘连新. 免疫治疗联合分子靶向药物治疗中晚期肝细胞癌的临床疗效及安全性分析:一项单臂回顾性研究[J]. 实用肿瘤学杂志, 2022, 36(6): 489-494.
[2]	杨菊, 刘芹, 刘宝瑞, 魏嘉. 胃癌相关癌睾抗原筛选与免疫浸润分析[J]. 实用肿瘤学杂志, 2022, 36(6): 495-501.
[3]	巩芮宁, 任贺. 胰腺导管腺癌免疫治疗研究现状和展望[J]. 实用肿瘤学杂志, 2022, 36(6): 502-506.
[4]	曹文杰, 魏瑗, 邝栋明. 肿瘤浸润B细胞与免疫治疗[J]. 实用肿瘤学杂志, 2022, 36(6): 507-512.
[5]	张玥, 汪越, 魏嘉. SHP2作为抗肿瘤治疗靶点的价值及其在肿瘤免疫治疗中的应用[J]. 实用肿瘤学杂志, 2022, 36(6): 513-519.
[6]	程思远, 韩子翰, 郭晓欢, 沈琳, 彭智. 肠道菌群与肿瘤免疫治疗疗效及不良反应关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 520-525.
[7]	李雄, 姜文凯, 郎泽昆, 芮少珍. 肿瘤相关中性粒细胞与胰腺癌关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 458-462.
[8]	童曼琳, 尚茹茹, 刘晓红. PD-1/PD-L1免疫检查点抑制剂在多形性胶质母细胞瘤中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 278-282.
[9]	吴芳芳, 郑桐森. 胆道恶性肿瘤辅助治疗的研究现状及展望[J]. 实用肿瘤学杂志, 2022, 36(2): 156-161.
[10]	唐菊, 尚利华. BMI与免疫检查点抑制剂治疗恶性肿瘤疗效的关系[J]. 实用肿瘤学杂志, 2022, 36(2): 188-192.
[11]	杨开炎, 韦永昌, 杨秋云, 唐凤珠. 鼻咽癌的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 542-546.
[12]	李响, 胡洋, 张清媛. 肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 568-571.
[13]	马明瑞, 连洁, 刘超, 娄长杰, 张艳桥. 消化系统肿瘤“免疫治疗前移”的探索[J]. 实用肿瘤学杂志, 2021, 35(3): 258-262.
[14]	王萌萌, 连洁, 李恒震, 张艳桥. 胃肠胰神经内分泌肿瘤的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 154-159.
[15]	王明明, 陈晓品. 抗PD-1/PD-L1和CTLA-4免疫治疗在头颈鳞癌中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 179-183.